Evidence map›Paper›PMID 20525369›Full record

ArticleBMC bioinformatics2010

Prediction of epigenetically regulated genes in breast cancer cell lines.

Leandro A Loss, Anguraj Sadanandam, Steffen Durinck, Shivani Nautiyal, Diane Flaucher, Victoria E H Carlton, Martin Moorhead, Yontao Lu, Joe W Gray, Malek Faham and 2 more

Abstract read
In one paragraph

Article in BMC bioinformatics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leandro A LossLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. laloss@lbl.gov
Anguraj Sadanandam
Steffen Durinck
Shivani Nautiyal
Diane Flaucher
Victoria E H Carlton
Martin Moorhead
Yontao Lu
Joe W Gray
Malek Faham
Paul Spellman
Bahram Parvin

Funding

Tissue and Outcomes CoreP50CA058207 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAY, JOE W. · 1992 to 2012
$32.7M
Systems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI GRAY, JOE W. · 2004 to 2014
$27.1M
NCI NIH HHS P50 CA058207NCI NIH HHS P50 CA 58207NCI NIH HHS U54 CA 112970NCI NIH HHS U54 CA112970
6 · The paper itself

Abstract

backgroundMethylation of CpG islands within the DNA promoter regions is one mechanism that leads to aberrant gene expression in cancer. In particular, the abnormal methylation of CpG islands may silence associated genes. Therefore, using high-throughput microarrays to measure CpG island methylation will lead to better understanding of tumor pathobiology and progression, while revealing potentially new biomarkers. We have examined a recently developed high-throughput technology for measuring genome-wide methylation patterns called mTACL. Here, we propose a computational pipeline for integrating gene expression and CpG island methylation profiles to identify epigenetically regulated genes for a panel of 45 breast cancer cell lines, which is widely used in the Integrative Cancer Biology Program (ICBP). The pipeline (i) reduces the dimensionality of the methylation data, (ii) associates the reduced methylation data with gene expression data, and (iii) ranks methylation-expression associations according to their epigenetic regulation. Dimensionality reduction is performed in two steps: (i) methylation sites are grouped across the genome to identify regions of interest, and (ii) methylation profiles are clustered within each region. Associations between the clustered methylation and the gene expression data sets generate candidate matches within a fixed neighborhood around each gene. Finally, the methylation-expression associations are ranked through a logistic regression, and their significance is quantified through permutation analysis.

resultsOur two-step dimensionality reduction compressed 90% of the original data, reducing 137,688 methylation sites to 14,505 clusters. Methylation-expression associations produced 18,312 correspondences, which were used to further analyze epigenetic regulation. Logistic regression was used to identify 58 genes from these correspondences that showed a statistically significant negative correlation between methylation profiles and gene expression in the panel of breast cancer cell lines. Subnetwork enrichment of these genes has identified 35 common regulators with 6 or more predicted markers. In addition to identifying epigenetically regulated genes, we show evidence of differentially expressed methylation patterns between the basal and luminal subtypes.

conclusionsOur results indicate that the proposed computational protocol is a viable platform for identifying epigenetically regulated genes. Our protocol has generated a list of predictors including COL1A2, TOP2A, TFF1, and VAV3, genes whose key roles in epigenetic regulation is documented in the literature. Subnetwork enrichment of these predicted markers further suggests that epigenetic regulation of individual genes occurs in a coordinated fashion and through common regulators.

Indexed as

Cell Line, TumorDNA MethylationEpigenesis, GeneticGene Expression Regulation, NeoplasticAntigens, NeoplasmBreast NeoplasmsCollagen Type ICollagen Type I, alpha 1 ChainCpG IslandsDNA-Binding ProteinsDNA Topoisomerases, Type IIGene Expression ProfilingGenes, Tumor SuppressorGenome-Wide Association StudyHumansOligonucleotide Array Sequence AnalysisAntigens, NeoplasmCollagen Type ICollagen Type I, alpha 1 ChainDNA-Binding ProteinsDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsProto-Oncogene Proteins c-vavTFF1 protein, humanTOP2A protein, humanTrefoil Factor-1Tumor Suppressor ProteinsVAV3 protein, human

Identifiers

PMID20525369
PMCPMC2903569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.